Study protocol: Health outcomes analysis of a strategy for deprescribing proton pump inhibitors.
e202502011
Keywords:
deprescribing, proton pump inhibitors, gastropathyAbstract
Background:
Proton pump inhibitors (PPI) are one of the groups of drugs with the highest prevalence of use. However, in many cases they are used for the treatment of unapproved indications. For this reason, in Navarra a strategy was implemented to deprescribe PPI in those cases in which their use was not indicated.
Subsequently, a project was designed in order to analyze the health outcomes of that PPI deprescription strategy.
Methods:
A retrospective cohort study will be developed to evaluate health outcomes obtained after the implementation of the PPI deprescription strategy. The primary outcome will be the time until a serious adverse event, defined as one that causes hospital admission or death. We will analyze whether there are differences between patients who stopped PPI treatment and those who maintained it.
Discussion:
It is expected to obtain information on the health outcomes of the proton pump inhibitor deprescription strategy and information about the convenience of continuing it.
Downloads
References
Shanika LGT, Reynolds A, Pattison S, Braund R. Proton pump inhibitor use: systematic review of global trends and practices. Eur J Clin Pharmacol. 2023;79(9):1159-1172. doi: https://dx.doi.org/10.1007/s00228-023-03534-z
Agencia Española de Medicamentos y Productos Sanitarios. [Consultado el 10 de septiembre de 2024]. https://cima.aemps.es/cima/publico/home.html
Nguyen PV-Q, Boidin C, Bouin M. Effectiveness of prescribing codes in reducing inappropriate proton pump inhibitors in ambulatory care. J Am Pharm Assoc (2003). 2023;63(4):1197-1202. doi: https://dx.doi.org/10.1016/j.japh.2023.05.006
Vidonscky Lüthold R, Henz NC, Fuhrer C et al. Inappropriate proton-pump inhibitor prescribing in primary care-an observational study with quality circles. Swiss Med Wkly. 2023;153:40119. doi: https://dx.doi.org/10.57187/smw.2023.40119
Çelik F, Aypak C, Özdemir A, Görpelioglu S. Inappropriate Prescribing of Proton Pump Inhibitors in Outpatient Clinics. Gastroenterol Nurs Off J Soc Gastroenterol Nurses Assoc. 2021;44(2):84-91. doi: https://dx.doi.org/10.1097/SGA.0000000000000500
Boster J, Lowry LE, Bezzant ML, Kuiper B, Surry L. Reducing the Inappropriate Use of Proton Pump Inhibitors in an Internal Medicine Residency Clinic. Cureus. 2020;12(1):e6609. doi: https://dx.doi.org/10.7759/cureus.6609
UpToDate. Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders. [Consultado el 10 de septiembre de 2024] https://www.uptodate.com/contents/proton-pump-inhibitors-overview-of-use-and-adverse-effects-in-the-treatment-of-acid-related-disorders
Chinzon D, Domingues G, Tosetto N, Perrotti M. Safety of long-term proton pump inhibitors: facts and myths. Arq Gastroenterol. 2022;59(2):219-225. doi: https://dx.doi.org/10.1590/S0004-2803.202202000-40
Ali MD. Proton Pump Inhibitors’ Use and Risk of Iron Deficiency Anaemia: A Systematic Review and Meta-analysis. Curr Rev Clin Exp Pharmacol. 2023;18(2):158-166. doi: https://dx.doi.org/10.2174/2772432817666220307121220
Boxer M. Iron deficiency anemia from iron malabsorption caused by proton pump inhibitors. EJHaem. 2020;1(2):548-551. doi: https://dx.doi.org/10.1002/jha2.96
Gommers LMM, Hoenderop JGJ, De Baaij JHF. Mechanisms of proton pump inhibitor-induced hypomagnesemia. Acta Physiol (Oxf). 2022;235(4):e13846. doi: https://dx.doi.org/10.1111/apha.13846
Anna Vermeulen Windsant-van den Tweel AM, Derijks HJ, Gadiot NPPM, Keijsers CJPW. Proton Pump Inhibitors and Hypomagnesemia in Older Inpatients: An Observational Study. Sr care Pharm. 2022;37(12):623-630. doi: https://dx.doi.org/10.4140/TCP.n.2022.623
Xun X, Yin Q, Fu Y, He X, Dong Z. Proton Pump Inhibitors and the Risk of Community-Acquired Pneumonia: An Updated Meta-analysis. Ann Pharmacother. 2022;56(5):524-532. doi: https://dx.doi.org/10.1177/10600280211039240
Tawam D, Baladi M, Jungsuwadee P, Earl G, Han J. The Positive Association between Proton Pump Inhibitors and Clostridium Difficile Infection. Inov Pharm. 2021;12(1). doi: https://dx.doi.org/10.24926/iip.v12i1.3439
Inghammar M, Svanström H, Voldstedlund M, Melbye M, Hviid A, Mølbak K et al. Proton-Pump Inhibitor Use and the Risk of Community-Associated Clostridium difficile Infection. Clin Infect Dis an Off Publ Infect Dis Soc Am. 2021;72(12):e1084-e1089. doi: https://dx.doi.org/10.1093/cid/ciaa1857
Seo SI, You SC, Park CH, Kim TJ, Ko YS, Kim Y et al. Comparative risk of Clostridium difficile infection between proton pump inhibitors and histamine-2 receptor antagonists: A 15-year hospital cohort study using a common data model. J Gastroenterol Hepatol. 2020;35(8):1325-1330. doi: https://dx.doi.org/10.1111/jgh.14983
AEMPS. Utilización de Medicamentos Antiulcerosos En España. 2024. [Consultado el 10 de septiembre de 2024] https://www.aemps.gob.es/medicamentos-de-uso-humano/observatorio-de-uso-de-medicamentos/informes/#
American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. doi: https://dx.doi.org/10.1111/jgs.18372
O’Mahony D, Cherubini A, Guiteras AR, Denkinger M, Beuscart JB, Onder G et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 3. Eur Geriatr Med. 2023;14(4):625-632. doi: https://dx.doi.org/10.1007/s41999-023-00777-y
Lavan AH, Gallagher P, Parsons C, O’Mahony D. STOPPFrail (Screening Tool of Older Persons Prescriptions in Frail adults with limited life expectancy): Consensus validation. Age Ageing. 2017;46(4):600-607. doi: https://dx.doi.org/10.1093/ageing/afx005
Alzueta Isturiz, N, Echeverria Gorriti A, Celaya Lecea MC, Fontela Bulnes MC, Sanz Álvarez L, Acin Gerico MT. Deprescripción de inhibidores de la bomba de protones en pacientes que no cumplen indicación de tratamiento. BMJ evidence-based Med. 2018;Suppl 2:A58-A59. doi: https://dx.doi.org/10.1136/bmjebm-2018-111070.124
Alzueta Isturiz, N, Echeverria Gorriti A, Celaya Lecea MC, Fontela Bulnes MC, Sanz Álvarez L AGM. Estrategia de optimización del tratamiento con inhibidores de la bomba de protones. Publicado en línea en 2018.
Boghossian TA, Rashid FJ, Thompson W, Welch V, Moayyedi P, Rojas-Fernandez C et al. Deprescribing versus continuation of chronic proton pump inhibitor use in adults. Cochrane Database Syst Rev. 2017;2017(3). doi: https://dx.doi.org/10.1002/14651858.CD011969.pub2
Calvini G, Baiardi G, Mattioli F, Milano G, Calautti F, Zunino A et al. Deprescribing Strategies: A Prospective Study on Proton Pump Inhibitors. J Clin Med. 2023;12(8). doi: https://dx.doi.org/10.3390/jcm12083029
Lamuela Calvo LJ, García Cámara P, Llorente Barrio M, Sierra Gabarda O, Monzón Baez R, Arbonés Mainar JM et al. Successful deprescribing of proton pump inhibitors with a patient-centered process: the DESPIBP Project. Eur J Clin Pharmacol. 2021;77(12):1927-1933. doi: https://dx.doi.org/10.1007/s00228-021-03186-x
Visser AGR, Schols JMGA, Prevoo MALM, Janknegt R, Winkens B. Deprescribing Statins and Proton Pump Inhibitors in Nursing Home Residents; a Pragmatic Exploratory Study. Gerontol Geriatr Med. 2021;7:23337214211050810. doi: https://dx.doi.org/10.1177/23337214211050807
Magin P, Quain D, Tapley A, van Driel M, Davey A, Holliday E et al. Deprescribing in older patients by early-career general practitioners: Prevalence and associations. Int J Clin Pract. 2021;75(8):e14325. doi: https://dx.doi.org/10.1111/ijcp.14325
Odenthal DR, Philbrick AM, Harris IM. Successful deprescribing of unnecessary proton pump inhibitors in a primary care clinic. J Am Pharm Assoc. 2020;60(1):100-104. doi: https://dx.doi.org/10.1016/j.japh.2019.08.012
Downloads
Published
Versions
- 2025-02-26 (3)
- 2025-02-26 (2)
- 2025-02-26 (1)
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Amaya Echeverría Gorriti, Andrea Rodríguez Esquiroz, Patricia García González, Lorea Sanz Álvarez, Marta Marín Marín, Javier Gorricho Mendívil, Julen Fernández González, Mª Concepción Celaya Lecea, Ana Campillo Arregui, Rebeca Irisarri Garde, Javier Garjón Parra
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.
